Takeda Pharmaceutical (NYSE:TAK) Insider Andrew Stewart Plump Sells 116,191 Shares

Takeda Pharmaceutical Co. (NYSE:TAK) insider Andrew Plump sold 116,191 shares of Takeda Pharmaceutical stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $18.49, for a total transaction of $2,148,371.59. Following the completion of the sale, the insider directly owned 145,465 shares of the company’s stock, valued at $2,689,647.85. The trade was a 44.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Stewart Plump also recently made the following trade(s):

• On Wednesday, August 19th, Andrew Plump sold 19,651 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $18.49, for a total value of $363,346.99.
• On Monday, August 10th, Andrew Plump sold 165,393 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $17.10, for a total value of $2,828,220.30.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $18.46 on Friday. The company has a market cap of $59.15 billion, a P/E ratio of 54.29 and a beta of -0.07. The business has a fifty day simple moving average of $17.32 and a 200-day simple moving average of $17.21. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.90. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.54. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The firm had revenue of $7.50 billion for the quarter, compared to analyst estimates of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Equities research analysts forecast that Takeda Pharmaceutical Co. will post 1.54 EPS for the current year.

Analyst Ratings Changes

TAK has been the topic of several research reports. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Finally, Zacks Research upgraded Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

Institutional Trading of Takeda Pharmaceutical

Institutional investors have recently added to or reduced their stakes in the business. Capital Research Global Investors raised its position in Takeda Pharmaceutical by 0.6% in the fourth quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock valued at $210,259,000 after purchasing an additional 82,643 shares during the period. UBS Group AG boosted its position in shares of Takeda Pharmaceutical by 46.4% in the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after buying an additional 1,869,323 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in shares of Takeda Pharmaceutical by 100.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after buying an additional 2,854,069 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Takeda Pharmaceutical by 15.0% in the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after buying an additional 692,404 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Takeda Pharmaceutical by 14.2% in the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after buying an additional 370,800 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.